Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease - Wikidata - wikimedia - TriplyDB

Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease

Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease

http://www.wikidata.org/entity/Q24244197

about

First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension Oral adsorbents for preventing or delaying the progression of chronic kidney disease Aldosterone antagonists for preventing the progression of chronic kidney disease Direct renin inhibitors for preventing the progression of diabetic kidney disease Rheum officinale (a traditional Chinese medicine) for chronic kidney disease Pentoxifylline for diabetic kidney disease Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease Non-immunosuppressive treatment for IgA nephropathy Aldosterone antagonists for preventing the progression of chronic kidney disease Antihypertensive treatment for kidney transplant recipients Oral adsorbents for preventing or delaying the progression of chronic kidney disease First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension Rheum officinale (a Chinese medicinal herb) for chronic kidney disease Angiotensin converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1-3) non-diabetic chronic kidney disease Aldosterone antagonists for preventing the progression of chronic kidney disease Protection against death and renal failure by renin-angiotensin system blockers in patients with diabetes and kidney disease.Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis.Diabetic Kidney Disease: A Syndrome Rather Than a Single Disease.Multifactorial control and treatment intensity of type-2 diabetes in primary care settings in Catalonia.Diabetic nephropathy: preventing progression Cost-effectiveness of angiotensin-converting enzyme inhibitors for the prevention of diabetic nephropathy in The Netherlands--a Markov model.Oxidative stress: implications for the development of diabetic retinopathy and antioxidant therapeutic perspectives.Enalapril versus losartan for adults with chronic kidney disease: a systematic review and meta-analysis.Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis.Screening for chronic kidney disease: preventing harm or harming the healthy?Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America.Hypokalemia, its contributing factors and renal outcomes in patients with chronic kidney disease.Diabetic nephropathy among Mexican Americans Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial.Diabetes and stroke prevention: a review.Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease Audit-based education lowers systolic blood pressure in chronic kidney disease: the Quality Improvement in CKD (QICKD) trial results.Derivation and validation of a renal risk score for people with type 2 diabetes Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials.Obstructive renal injury: from fluid mechanics to molecular cell biology Angiotensin blockade to reduce microvascular damage in diabetes mellitus.Determinants of urinary albumin excretion within the normal range in patients with type 2 diabetes: the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.The goal of blood pressure in the hypertensive patient with diabetes is defined: now the challenge is go from recommendations to practice.Glomerular filtration rate decline as a surrogate end point in kidney disease progression trials.

P2860

Q24186647-970D5A04-FE02-4187-B6DA-05361E622905 Q24193105-CD6937EA-5C14-45DD-AD4E-5C21EC9B8DC2 Q24194979-5C275C29-A1DC-46EF-A7A5-27E23B0ED83F Q24198989-E95252B2-9617-4F94-827C-8074073D72C9 Q24202076-854275BE-A31A-42F2-AAA7-384B35669CF5 Q24203643-66AAF831-BC5E-4ABD-94E8-436B05F1E628 Q24235834-F0EB1D19-EA5C-4002-A2D5-B5E82C171CB3 Q24235956-9B178C74-9E37-4FF7-9858-78E746A6F61D Q24239909-734B9061-F6E2-4194-8021-58BC1242FC72 Q24240164-7FE02D21-6DB9-411D-AC8F-B114DC7B138E Q24240604-1325D093-45E5-49B2-BC33-39CF0A7DFDE4 Q24240851-E4D23F04-AB07-405B-BC4E-57FE2B308DBF Q24241536-A2ED311C-C9E9-46CA-B1FF-1A279C00A706 Q24241947-CA21B10C-EE96-4874-8612-314FDCB0E40E Q24243615-A08B4D7B-BA98-44DD-A260-F0347F6ADBEF Q30249156-6936F682-59C4-45D8-B3B8-F271FB0952A5 Q33414957-726A1005-581D-42B5-AB7A-F84CDFE11F06 Q33583012-02A064E6-6B4A-4E33-A067-130D1F7A62BE Q33804396-D4F9CE4A-532B-4E0D-9B61-D5787B5767F9 Q33850444-F28F7FB5-49CF-41A6-A017-D8D79EE3B460 Q34056044-0A72D19B-17CD-4A9D-8371-40E7E8EA9F8B Q34081808-DF35F471-6F38-4ABB-ADA5-357CC0338C76 Q34358545-3A34D69E-35A4-494C-AF29-3DACC04AF854 Q34380070-60BB5F12-CF6E-474F-A33E-97464A241223 Q34489522-AB478972-8C13-4CE6-AF5A-3A1CFD500254 Q34736194-041441F3-FC9E-40B0-BF29-3381889F4D41 Q34812460-FA982E03-376C-4F6C-882A-DC9F87CFA6EA Q35530323-076FA530-F2AC-486D-8F89-975C93790F3D Q36127484-7B7A7EE2-6A2D-464C-8BF4-7FEF1293E9E0 Q36497887-32656730-B301-45D2-8750-33C83C2CCCA9 Q36528473-BB877232-70FE-4321-BCF1-877EFCEE9727 Q36796750-E7F2B67E-B145-4DC6-8ED9-6934ED35ED22 Q37186899-BFEE3D91-CF20-4A79-9C87-1032AA5F85A3 Q37193467-7EEDABB8-72E2-47B4-AAFB-97902AFFD890 Q37213061-167C4235-C4C1-49FE-AB37-0979BD349B9A Q37283558-C03EB235-B39E-483A-8A9C-5B7BBB1CE727 Q37369097-0802E613-176D-4C19-8DFA-EF710C7C9250 Q37463910-351255C5-9CCD-442F-A6C6-DAD81A9E299E Q37681363-95197142-70FE-469F-8EEE-844CB8733A90 Q38545232-AA31F036-0F45-4F97-9499-56C98CE9D419

P2860

Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease

http://www.wikidata.org/entity/Q24244197

description

2006 nî lūn-bûn

@nan

2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Angiotensin converting enzyme ...... ion of diabetic kidney disease

@ast

Angiotensin converting enzyme ...... ion of diabetic kidney disease

@en

Angiotensin converting enzyme ...... ion of diabetic kidney disease

@en-gb

Angiotensin converting enzyme ...... ion of diabetic kidney disease

@nl

type

label

Angiotensin converting enzyme ...... ion of diabetic kidney disease

@ast

Angiotensin converting enzyme ...... ion of diabetic kidney disease

@en

Angiotensin converting enzyme ...... ion of diabetic kidney disease

@en-gb

Angiotensin converting enzyme ...... ion of diabetic kidney disease

@nl

prefLabel

Angiotensin converting enzyme ...... ion of diabetic kidney disease

@ast

Angiotensin converting enzyme ...... ion of diabetic kidney disease

@en

Angiotensin converting enzyme ...... ion of diabetic kidney disease

@en-gb

Angiotensin converting enzyme ...... ion of diabetic kidney disease

@nl

P1433

Q24244197-B4E6EFCF-CC4E-49AE-A011-B9D4332B5808

P1476

Q24244197-A93AF4C1-CE3F-4059-B6C9-346C31012AE3

P2093

Q24244197-45037AED-00A0-4878-8A92-33E9AD9D6905

Q24244197-7E63B200-9D0A-4304-A77B-377FD7233217

Q24244197-BC35D98F-A134-4491-AA77-38A373C0423B

Q24244197-E52BBB17-73FD-4EFA-80EF-7B8DF9D59A54

P2860

Q24244197-0765EC03-E7E0-4B4A-AE4A-7E03EAED54C8

Q24244197-08B3028D-3374-4BA7-90A3-493826255840

Q24244197-111D8E7C-8B11-48F3-8932-6EB3E17D2D04

Q24244197-1454A17F-71F6-4F09-90B3-2DDC839BA317

Q24244197-1C87DB9E-C0EE-4075-9737-736B68175147

Q24244197-37B46D68-42BE-4AC6-91CC-C040085670F6

Q24244197-4481140B-2DE5-4375-930F-0C0219D7D636

Q24244197-498B785B-3E6A-4915-B5B7-63C643484735

Q24244197-4FACC42F-277F-4AD7-9C29-802B5764C2A4

Q24244197-5C3B124E-132D-4667-BC7D-7CACD5E40D4F

P304

Q24244197-68634B2A-B723-445C-90E1-213D71B2D059

P31

Q24244197-4d93c20e-4268-4c35-8aa1-11e93c284556

Q24244197-8A72D866-6742-4AC8-96C4-BC8E17627040

P3181

Q24244197-84F12E8C-1A92-491F-B686-67257776DC4A

P356

Q24244197-EF4FA0D3-00E9-4B56-816E-39653B77D516

P433

Q24244197-13303308-9C75-4F8B-80BC-BB76B8ACB7D2

P50

Q24244197-4AE8C884-7AF6-4CB7-953F-A09FD244C4A2

P577

Q24244197-1F5CFAD5-A3E2-40B5-8EDE-2C98B6F16C89

P698

Q24244197-8D529A8B-CA66-4DA0-80D2-2072535C88C9

P932

Q24244197-31F6D641-C797-4F31-B564-2646FE81360F

P3181

P356

14651858.CD006257

P1433

Cochrane Database of Systematic Reviews

P1476

Angiotensin converting enzyme ...... ion of diabetic kidney disease

@en

P2093

C Bonifati

http://www.w3.org/2001/XMLSchema#string

J C Craig

http://www.w3.org/2001/XMLSchema#string

M Craig

http://www.w3.org/2001/XMLSchema#string

S D Navaneethan

http://www.w3.org/2001/XMLSchema#string

P2860

Antihypertensive agents for preventing diabetic kidney disease

Measuring inconsistency in meta-analyses

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data.

Nephropathy in patients with type 2 diabetes mellitus.

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.

P304

CD006257

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3620255

http://www.w3.org/2001/XMLSchema#string

P356

10.1002/14651858.CD006257

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P50

Giovanni Strippoli

P577

2006-10-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17054288

http://www.w3.org/2001/XMLSchema#string

P932

6956646

http://www.w3.org/2001/XMLSchema#string